Skip to content

Tagaradi Capsule in insomnia

Role of Tagaradi Capsule in the management of Anidra (Insomnia)

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/03/008084
Enrollment
100
Registered
2017-03-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F489- Nonpsychotic mental disorder, unspecified Health Condition 2: null- patients suffering from insomnia

Interventions

Intervention1: Tagaradi Capsule: 2 capsules of 500 mg with luke warm milk once at bedtime for 8 weeks Control Intervention1: Placebo (starch) capsule: 2 capsules of 500 mg with luke warm milk once at

Sponsors

IPGT RA GAU Jamnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of both sexes in between the age group 18-75 years. 2. Patients suffering from following type of disturbed sleep pattern. 1) Sleep onset insomnia (Difficulty to taking sleep at the beginning of the night) 2) Sleep maintenance insomnia (Difficulty to maintain the sleep) 3) Nocturnal awakening (Difficulty to returning to sleep after awakening in the middle of the night or wakening early in the morning) 4) Rebound insomnia (Patients who has developed dependence to sedatives) 5) Circadian rhythm disorders (Sleeping pattern changes) 6) Patients having insomnia more than 2 weeks, less than 6 months 3. Patients of insomnia with mild hypertension, mild depression and anxiety disorders without any complains of other major diseases.

Exclusion criteria

Exclusion criteria: •Patients less than 18 years and more than 75 years. •Patients suffering from fatal familial insomnia. •Insomnia with major psychiatric illness like, Schizophrenia, Depressive psychosis, Epilepsy, etc. •Patients having advanced chronic illness like Bronchial asthma, Diabetes mellitus, Malignancy, Liver cirrhosis, Chronic renal failure, etc. •Patients with alcohol or drug dependency will be excluded. •Patients having acute illness like Cardiovascular accidents, Myocardial infarction, Chronic obstructive pulmonary disease. •Pregnant woman and planning to be pregnant within six months.

Design outcomes

Primary

MeasureTime frame
relief in signs and symptoms of Anidra (Insomnia)Timepoint: 8 weeks

Secondary

MeasureTime frame
relief in signs and symptoms of Anidra (Insomnia) and regular normal sleepTimepoint: 8 weeks

Countries

India

Contacts

Public ContactDr A R Dave

IPGT RA Jamnagar Gujarat

alankruta@yahoo.com9824171817

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026